Ozempic Market to Reach USD 113.95 Billion as Demand for GLP-1 Therapies Accelerates, Reports Mordor Intelligence

The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.

11/06/2026, 9:00 AM • GlobeNewswire

Novo Nordisk: 3 Key Takeaways for Long-Term Investors

Novo Nordisk reported Q3 2026 earnings with raised full-year guidance and returned to volume growth despite U.S. pricing pressure. The company added 1.3 million patients in the quarter, is expanding its Wegovy pill to over 20 markets by mid-2027, and its next-generation CagriSema treatment demonstrated superior weight loss (12.4%) compared to tirzepatide (9.1%) in trials.

11/04/2026, 8:55 PM • The Motley Fool

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

Viking Therapeutics is trading 23% below its recent $35 secondary offering price after raising $575 million for phase 3 development of its weight loss drug VK2735. Despite the post-offering stock decline due to dilution concerns, the article argues this presents a buying opportunity for patient investors, as Viking is advancing dual GLP-1/GIP receptor agonist candidates in injectable and oral formats while the weight loss drug market is projected to reach nearly $100 billion by decade's end.

11/04/2026, 7:15 AM • The Motley Fool

Sickle Cell Disease Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.

11/03/2026, 1:00 PM • GlobeNewswire

Semaglutide Market Forecast 2027–2032: Valuation to Hit USD 64.51 Billion as Diabetes and Weight Management Demand Expands, Reports Mordor Intelligence

The semaglutide market is projected to grow from USD 36.1 billion in 2027 to USD 64.51 billion by 2032, at a CAGR of 12.31%. North America leads with 45.64% market share, while Asia-Pacific is the fastest-growing region at 16.4% CAGR. Growth is driven by rising obesity and diabetes prevalence, expanded formulations, and broader access channels, though high costs and reimbursement limitations remain challenges.

11/02/2026, 2:00 PM • GlobeNewswire

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are revolutionizing healthcare with massive growth potential. Beyond weight loss and diabetes, research shows these drugs may treat cardiovascular, kidney, liver, and other diseases, with emerging evidence of anti-aging benefits. Morgan Stanley forecasts the obesity drug market will reach $190 billion by 2035, but the author believes this is understated given untapped international markets and expanding use cases.

11/02/2026, 9:00 AM • The Motley Fool

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

UBS initiated buy coverage of Viking Therapeutics (VKTX) with a $94 price target, implying 250% upside from current levels. The clinical-stage biotech's experimental weight loss drug VK2735 has shown promising results, potentially delivering twice the weight loss of semaglutide and 1.5x that of tirzepatide. Viking is advancing both injectable and oral formulations into phase 3 trials and raised $575 million in September to fund development, though the company faces competition from established players and regulatory risks.

11/02/2026, 7:22 AM • The Motley Fool

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Novo Nordisk's stock has declined 70% from its 2024 high, trading at a 10x P/E ratio compared to its 5-year average of 24x. Despite losing market share to Eli Lilly in GLP-1 weight-loss drugs due to supply issues and efficacy concerns, the company is shifting to a volume-driven model with a pill version of its drug and has initiated a $2.2 billion stock buyback. The article suggests this valuation may represent an opportunity for long-term investors, supported by a 4.6% dividend yield.

11/01/2026, 9:15 AM • The Motley Fool

After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

Eli Lilly reported strong Q3 earnings driven by its weight loss drug portfolio, with Mounjaro and Zepbound sales surging 65% and 49% respectively. The company now holds 63% of the U.S. weight loss drug market, up from competitor Novo Nordisk. While the stock trades at a record high of $1,300+ at 42x forward earnings, analysts suggest significant growth potential remains as only 3-10% of potential patients currently access weight loss care, with additional pipeline candidates in development.

10/31/2026, 6:10 PM • The Motley Fool

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight

The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.

10/29/2026, 1:00 PM • GlobeNewswire

Sofie Mørck Jarl bliver ny CFO i Københavns Lufthavne A/S

Copenhagen Airports A/S has appointed Sofie Mørck Jarl as its new CFO, effective March 1, 2027. She joins from Novo Nordisk where she served as Group Vice President for Finance & Business Support, bringing experience in financial leadership, strategy, and major investment management. She replaces Rasmus Lund, who passed away unexpectedly in July.

10/28/2026, 5:00 AM • GlobeNewswire

Sofie Mørck Jarl appointed new CFO at Copenhagen Airports A/S

Copenhagen Airports A/S has appointed Sofie Mørck Jarl as its new CFO, effective no later than 1 March 2027. Jarl joins from Novo where she served as Group Vice President for Finance & Business Support, and previously worked as CFO at Novo Nordisk Engineering A/S. She succeeds Rasmus Lund, who passed away in July. The CEO praised her extensive financial and strategic expertise, particularly her experience managing major investments and complex projects.

10/28/2026, 5:00 AM • GlobeNewswire

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

10/27/2026, 10:50 AM • The Motley Fool

Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed VanEck Pharmaceutical ETF (PPH) over the past year, driven by concentrated exposure to Eli Lilly's GLP-1 drugs, delivering 38.2% returns versus PPH's 26.4%. However, PPH offers global diversification with European pharma giants, a higher dividend yield of 1.9%, and nearly identical expense ratios. IHE suits investors seeking recent momentum, while PPH appeals to those prioritizing international exposure and income.

10/26/2026, 11:40 AM • The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.

10/22/2026, 7:10 AM • The Motley Fool